IL-10 in myeloma cells

Leuk Lymphoma. 2002 May;43(5):969-74. doi: 10.1080/10428190290021579.


In addition to interleukin (IL)-6, IL-10 is considered as one of the most important cytokines regulating the proliferation and cellular characteristics of myeloma cells. It is still unclear from the clinical data how serum IL-10 levels of various stages of myeloma, are related to clinical manifestations of this disease. Several studies have reported that IL-10 affects myeloma cells by stimulating secondary signals for cell proliferation through oncostatin M (OSM) and IL-11. In experiments using human myeloma cell lines established at our laboratory, IL-10 seemed to be expressed in half of myelomas simultaneously with OSM, and to be correlated with c-maf, a transcription factor, which has been known to be overexpressed in myelomas with t(14;16)(q32;q23). In addition, IL-10 abolishes all trans retinoic acid (ATRA)-induced growth inhibition of myeloma cells. The expression and production of IL-10 in myeloma patients may be important for sub-categorization and the establishment of a case-oriented therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Division
  • Cytokines / physiology
  • Humans
  • Interleukin-10 / blood
  • Interleukin-10 / genetics
  • Interleukin-10 / physiology*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / immunology
  • Multiple Myeloma / pathology*
  • Tretinoin / therapeutic use


  • Cytokines
  • Interleukin-10
  • Tretinoin